Q-omics provides the consensus-scored CHRNA7 profile across patient tissues and cancer cell-line models. CHRNA7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHRNA7 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, CHRNA7 RNA expression shows 18,704 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where CHRNA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHRNA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHRNA7 survival associations across molecular data types. CHRNA7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHRNA7 RNA expression–survival associations across cancer types. High CHRNA7 expression shows unfavorable associations in ACC, STAD, LUAD and ESCA, but favorable associations in LGG and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHRNA7 RNA expression.
This table summarizes CHRNA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CHRNA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHRNA7 shows lower tumor expression in THCA, BRCA, PRAD and KICH and higher tumor expression in LUSC and KIRP. The THCA box plot shows higher CHRNA7 RNA expression in normal versus tumor tissue (log2 FC = −0.392, t-test p < 0.001).
This table shows molecular features associated with CHRNA7 in patient tissues and cancer cell lines. In patient samples, CHRNA7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CHRNA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
